Pugh, SA;
Bowers, M;
Ball, A;
Falk, S;
Finch-Jones, M;
Valle, JW;
O'Reilly, DA;
... Primrose, JN; + view all
(2016)
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
British Journal of Cancer
, 115
(4)
pp. 420-424.
10.1038/bjc.2016.208.
Preview |
Text
bjc2016208a.pdf - Published Version Download (250kB) | Preview |
Abstract
Background: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome. Methods: A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012. Results: The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent. Conclusions: Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery.
| Type: | Article |
|---|---|
| Title: | Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/bjc.2016.208 |
| Publisher version: | http://dx.doi.org/10.1038/bjc.2016.208 |
| Language: | English |
| Additional information: | This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology, colorectal liver metastases, colorectal cancer, cetuximab, epidermal growth factor inhibition, chemotherapy, liver resection, progressive disease, cancer research UK, METASTATIC COLORECTAL-CANCER, RESECTABLE LIVER METASTASES, RANDOMIZED CONTROLLED-TRIAL, REPEAT HEPATECTOMY, SURGERY, CHEMOTHERAPY, 5-FLUOROURACIL, OXALIPLATIN, LEUCOVORIN, CETUXIMAB |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1514925 |
Archive Staff Only
 |
View Item |
